# Discovery of Novel Triazole-Based Opioid Receptor Antagonists

**Qiang Zhang**[‡,†], **Susan M. Keenan**[‡], **Youyi Peng**[‡], **Anil C. Nair**[∥,#], **Seong Jae Yu**[∥,§], **Richard D. Howells**[⊥], and **William J. Welsh**[*,‡]

*Department of Pharmacology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey (UMDNJ) and UMDNJ Informatics Institute, Piscataway, New Jersey 08854, Department of Chemistry and Biochemistry, University of Missouri—St. Louis, St. Louis, Missouri 63121, and Department of Biochemistry and Molecular Biology, New Jersey Medical School, UMDNJ, Newark, New Jersey 07101*

## Abstract

We report the computer-aided design, chemical synthesis, and biological evaluation of a novel family of $\delta$ opioid receptor (DOR) antagonists containing a 1,2,4-triazole core structure that are structurally distinct from other known opioid receptor active ligands. Among those $\delta$ antagonists sharing this core structure, **8** exhibited strong binding affinity ($K_i$ = 50 nM) for the DOR and appreciable selectivity for $\delta$ over $\mu$ and opioid receptors ($\delta/\mu$ = 80; $\delta/\kappa$ > 200).

Opioid analgesics are the mainstay for treatment of moderate to severe pain. Research on opioids and their receptors has remained active over the past decade.[1] Three opioid receptor subtypes, designated as $\delta$, $\kappa$, and $\mu$, have been identified in the central nervous system (CNS) and periphery[2,3] and are products of three distinct and extensively studied genes. Recent evidence suggests that subtype-selective opioid receptor agonists and antagonists offer great potential as therapeutic agents devoid of the numerous adverse side effects (e.g., respiratory depression, physical dependence, and gastrointestinal effects) associated with morphine.[4] In particular, $\delta$-selective antagonists have been shown to modulate the development of tolerance[5,6] and dependence on $\mu$ agonists such as morphine,[7] to offset the behavioral effects of drugs of abuse such as cocaine,[8] and to elicit favorable immunomodulatory[9] and emotional effects.[10] On the other hand, $\delta$-selective agonists have been shown to elicit the prototypical analgesic effects of clinically available opioids.[4] They may also provide unique benefits as cardioprotective and neuroprotective agents[11] and as treatments for depression and anxiety.[12,13]

In view of their broad range of pharmacological applications, the $\delta$-selective opioids have attracted interest in our laboratory and elsewhere. Given the paucity of high-quality X-ray crystal structure data for GPCRs such as the opioid receptor, our drug design strategy has relied on ligand-based molecular modeling approaches. An additional component of our drug

* To whom correspondence should be addressed. Phone: 732−235−3234. Fax: 732−235−3475. E-mail: E-mail: welshwj@umdnj.edu..
‡University of Medicine and Dentistry of New Jersey and UMDNJ Informatics Institute.
†Present address: Intra-Cellular Therapies, Inc., 3960 Broadway, New York, NY 10032.
∥University of Missouri—St. Louis.
#Present Address: Sanofi-Aventis Pharmaceuticals, Inc., 1580 E. Hanley Boulevard, Oro Valley, Tucson, AZ 85737.
§Present Address: FMC Corporation, Agricultural Products Group, Princeton, NJ 08543.
⊥New Jersey Medical School.

discovery paradigm is the proprietary Shape Signatures computational tool that provides unique capabilities for scaffold hopping in the search for new lead compounds.[14,15]

A three-point pharmacophore was extracted by overlaying a series of high-affinity opioid receptor ligands including the $\delta$-antagonist naltrindole.[16] This pharmacophore model (Figure 1, gray) comprised the basic nitrogen atom, the centroid of the phenol ring (A), and the centroid of the hydrophobic ring (B). Virtual screening of an in-house database of ~1.2 million commercially available small-molecule chemicals was conducted to identify structures matching this three-point pharmacophore. Additional molecular models were developed for a distinct series of DOR-selective agonists[17] and antagonists[18] to demonstrate the structural requirement for $\delta$ selectivity. Promising chemical entities were then subjected to filters using an expanded Lipinski rule of five[19] hierarchical scheme. The substituted 1,2,4-triazoles (Figure 1) emerged from this scheme as an interesting core structural framework for our DOR active agents. In selecting appropriate substitution patterns for the 1,2,4-triazole ring to confer $\delta$ binding affinity and selectivity, we exploited the "message–address" concept[20,21] associated with classical morphine-like opioids. For instance, a sterically bulky group (e.g., *tert*-butyl) was attached to the B aryl group to mimic the $\delta$ "address" in our 1,2,4-triazoles. Several di- and trisubstituted 1,2,4-triazoles (Table 1) were selected for chemical synthesis and biological evaluation. Structural alignment of naltrindole and **8** in the conformation adopted in its X-ray crystal structure reveals good overlap between the *tert*-butyl group of **8** and the $\delta$ "address" of naltrindole (Figure 2, Supporting Information).

Three separate reaction schemes were developed for the synthesis of the 1,2,4-triazoles (Scheme 1) with thioamides as key intermediates. In most cases, thioamides were synthesized from the corresponding amides.[22,23] For **1**, **2**, **10**, and **16**, a coupling reaction of arylmagnesium reagents with isothiocyanates was conducted to synthesize the thioamides.[24,25] Amidrazones could be efficiently prepared by reaction of thioamides with excess hydrazine at room temperature. Cyclization of amidrazones with different reagents led to products with methoxyl groups at the $R_2$ positions. **1−7** were obtained using trimethyl orthoformate as the cyclization reagent,[26] while **8−15** involved cyclization of amidrazones with phosgeninium salts (Viehe's salts), which were easily synthesized from the corresponding amines.[27] Compounds **16** and **17** were synthesized from **1** and **3**, respectively, through reaction with Eschenmoser's salt.[28,29] Compound **18** was prepared directly by condensation of amidrazone with 3-*N*,*N*-dimethylaminopropionic acid hydrochloride in the presence of dicyclohexyldiimide (DCC) (Scheme 1). For most of the products, the final step of cleaving methoxyl groups at $R_2$ was completed easily by reaction with $BBr_3$ in dichloromethane. Where hydrolysis of the methoxyl group was incomplete using the above $BBr_3$ procedure, excess NaSH was added to achieve ether cleavage in acceptable yields.

Initially, **1−4** were synthesized to evaluate the feasibility of our approach (Table 1). Radioligand binding assays revealed that **2** binds to all three opioid receptors with $K_i$ values of 230 ($\delta$), 850 ($\mu$), and 1500 ($\kappa$) nM, respectively. As anticipated, it exhibited some subtype selectivity for the $\delta$ over $\mu$ and $\kappa$ opioid receptors. Structural analogues (**5−18**) were synthesized in order to increase the $\delta$ binding affinity and selectivity (Table 1). Several of the subject compounds (e.g., **5**, **8**, **11**, **12**) exhibited selectivity for the $\delta$ over $\mu$ and $\kappa$ opioid receptors, which concurs with our initial design strategy to confer $\delta$ selectivity. The inhibitory activity was much greater at all three opioid receptors for compounds with $R_1$ = OH (**2** and **4**) compared with $R_1$ = $OCH_3$ (**1** and **3**). In fact, the latter compounds showed very limited inhibitory activity for any of the opioid receptors even at 10 $\mu$M. Comparison of **8** and **14** indicates that the binding affinity for all three opioid receptor subtypes was virtually abolished when the hydroxyl substituent at $R_1$ is moved from the meta to para position on the aromatic ring. Although this single example precludes making generalizations, the strong preference for the meta over para phenolic moiety is consistent with the familiar SAR of morphine-like opioids.[30–33]

For **1−7**, $R_2$ substitutions were preferred at the meta position over the para position (e.g., $K_i(\delta)$ = 230 nM for **2** vs ~10 000 nM for **4**). For compounds with $R_3$ substitutions, namely **8 −17**, the opposite trend was observed in cases exhibiting an appreciable affinity difference (see **8** vs **10**). Compound **8** ($K_i(\delta)$ = 50 nM), with $R_2$ = *p-tert*-butyl and $R_3$ = $N(CH_3)_2$, yielded the best results overall among this first generation of triazole-based opioid receptor active agents in terms of $\delta$ binding affinity and subtype selectivity. It is worth noting that introduction of groups more highly constrained than *tert*-butyl at $R_2$ failed to increase binding affinity for the $\delta$ receptor. For example, the $\delta$ binding affinity was poorer for **11**, **12** and **13** ($K_i$ = 150, 130, and 480 nM, respectively) than for **8** ($K_i$ = 50 nM).

The functional activity of our substituted 1,2,4-triazoles on the opioid receptors was determined by receptor up-regulation assays. Incubation of the $\delta$ opioid receptor with **2** and **8** produced a sharp increase in receptor expression, suggesting that the subject compounds are $\delta$ opioid antagonists (Figure 2). Interestingly, **8** exhibited >3-fold up-regulation of the $\delta$ opioid receptor in this assay. The pharmacological significance of this observation is currently under investigation in our laboratory.

In fact, a *N,N*-dimethylamino group at $R_3$ did produce a sharp increase in binding affinity to the $\delta$ receptor. Compare, for example, the $K_i(\delta)$ of **8** (50 nM, $R_3$ = $N(CH_3)_2$) with its simple homologue **4** (~10 000 nM, $R_3$ = H). One might reasonably attribute the greater activity of **8** over **4** to the strong basicity of the N atom at $R_3$. Nevertheless, **8** is only slightly more basic than **4** ($pK_a$(pred) = 3.36 vs 2.18).[17] Ab initio quantum mechanical calculations on **8** at the HF/6−31G** level of theory, in vacuum and aqueous (implicit solvation) conditions, indicated that the most basic atom is not the N in $R_3$ = $N(CH_3)_2$ (i.e., $N_{sub}$) but rather $N_1$ or $N_2$ in the triazole ring (Table 2). Among the four N atoms in **8**, the rank of basicity is $N_1 \sim N_2 > N_{sub} > N_4$. These results suggest that $N_{sub}$ is less basic than the triazole-ring atoms $N_1$ and $N_2$, although it should be restated that all of the N atoms in **8** are weakly basic. It is evident that the basicity of the $N(CH_3)_2$ group is mitigated by its strong conjugation with the triazole ring. One might suspect that disrupting this conjugation by extension of the substituent group would afford a basic N atom and thereby enhance binding affinity. However, **17** ($R_3$ = $CH_2N(CH_3)_2$) and **18** ($R_3$ = $(CH_2)_2N(CH_3)_2$) showed >6-fold decrease in binding affinity to the DOR compared with **8**.

In conclusion, we report here a novel family of $\delta$-selective opioid receptor antagonists containing the 1,2,4-triazole core structure. The subject compounds are chemically and structurally distinct from the classical opioids such as morphine and other known small-molecule opioids (e.g., (+)-4-[($\alpha$)*R*]-$\alpha$-((2*S*,5*R*)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-*N,N*-diethylbenzamide (SNC80)). Moreover, these compounds are synthetically accessible as pure compounds in high yield and, uncommon among opioids, lack chiral centers. Compound **8**, the most active among this first generation of substituted 1,2,4-triazoles, exhibited strong binding affinity ($K_i$ = 50 nM) and appreciable selectivity (selectivity ratio: $\delta/\mu$ = 80; $\delta/\kappa$ > 200) for the $\delta$ opioid receptor. The weak basicity of **8** ($pK_a$(pred) = 3.36) favors the neutral (unprotonated) form under physiological conditions (pH 7.4). Virtually all known opioids, whether agonists or antagonists, contain at least one basic N atom. The only exception to our knowledge is the agonist salvinorin A, a natural compound extracted from *S. divinorum*,[34] and a series of cyclic peptides reported by Schiller et al.[35] that act as $\delta$ and $\mu$ receptor antagonists. The present compounds thus represent the first nonpeptidic $\delta$-selective opioid antagonists lacking a basic N atom.

## Acknowledgment

## References

1. Ananthan S, Khare NK, Saini SK, Seitz LE, Bartlett JL, Davis P, Dersch CM, Porreca F, Rothman RB, Bilsky EJ. Identification of opioid ligands possessing mixed micro agonist/δ antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J. Med. Chem 2004;47:1400–1412. [PubMed: 14998329]

2. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science 1973;179:1011–1014. [PubMed: 4687585]

3. Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. Annu. Rev. Pharmacol. Toxicol 2000;40:389–430. [PubMed: 10836142]

4. Bilsky EJ, Calderon SN, Wang T, Bernstein RN, Davis P, Hruby VJ, McNutt RW, Rothman RB, Rice KC, Porreca F. SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. J. Pharmacol. Exp. Ther 1995;273:359–366. [PubMed: 7714789]

5. Kest B, Lee CE, McLemore GL, Inturrisi CE. An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Res. Bull 1996;39:185–188. [PubMed: 8866695]

6. Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP, Unterwald E, Pasternak GW, Pintar JE. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 1999;24:243–252. [PubMed: 10677041]

7. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J. Pharmacol. Exp. Ther 1991;258:299–303. [PubMed: 1649297]

8. Reid LD, Hubbell CL, Glaccum MB, Bilsky EJ, Portoghese PS, Porreca F. Naltrindole, an opioid delta receptor antagonist, blocks cocaine-induced facilitation of responding for rewarding brain stimulation. Life Sci 1993;52:PL67–PL71. [PubMed: 8382329]

9. House RV, Thomas PT, Kozak JT, Bhargava HN. Suppression of immune function by non-peptidic delta opioid receptor antagonists. Neurosci. Lett 1995;198:119–122. [PubMed: 8592635]

10. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gaveriaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer BL. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat. Genet 2000;25:195–200. [PubMed: 10835636]

11. Barry U, Zuo Z. Opioids: old drugs for potential new applications. Curr. Pharm. Des 2005;11:1343–1350. [PubMed: 15853689]

12. Torregrossa MM, Isgor C, Folk JE, Rice KC, Watson SJ, Woods JH. The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacology 2004;29:649–659. [PubMed: 14647482]

13. Nieto MM, Guen SL, Kieffer BL, Roques BP, Noble F. Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors. Neuro-science 2005;135:305–313.

14. Nagarajan K, Zauhar R, Welsh WJ. Enrichment of ligands for the serotonin receptor using the Shape Signatures approach. J. Chem. Inf. Model 2005;45:49–57. [PubMed: 15667128]

15. Zauhar RJ, Moyna G, Tian L, Li Z, Welsh WJ. Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design. J. Med. Chem 2003;46:5674–5690. [PubMed: 14667221]

16. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol. Pharmacol 1994;45:330–334. [PubMed: 8114680]

17. Peng Y, Keenan SM, Zhang Q, Welsh WJ. 3D-QSAR comparative molecular field analysis on opioid receptor agonists SNC80 and its analogs. J. Mol. Graphics Modell 2005;24:72–80.

18. Peng Y, Keenan SM, Zhang Q, Kholodovych V, Welsh WJ. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies. J. Med. Chem 2005;48:1620–1629. [PubMed: 15743203]

19. Lipinski C. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000;44:235–249. [PubMed: 11274893]

20. Portoghese PS. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci 1989;10:230–235. [PubMed: 2549665]

21. Schwyzer R. ACTH: a short introductory review. Ann. N. Y. Acad. Sci 1977;297:3–26. [PubMed: 211904]

22. Curphey TJ. Thionation with the reagent combination of phosphorus pentasulfide and hexamethyldisiloxane. J. Org. Chem 2002;67:6461–6473. [PubMed: 12201768]

23. Metzner, P.; Thuillier, A. Sulfur Reagents in Organic Synthesis. Academic Press; New York: 1994. p. 44-46.

24. Dohle W, Lindsay DM, Knochel P. Copper-mediated cross-coupling of functionalized arylmagnesium reagents with functionalized alkyl and benzylic halides. Org. Lett 2001;3:2871–2873. [PubMed: 11529778]

25. Zhang, Q.; Peng, Y.; Welsh, WJ. Efficient synthesis of *N,N*-dialkylamino-1,2,4-triazoles.. Manuscript in preparation

26. Larsen SD, DiPaolo BA. Traceless solid-phase synthesis of 1,2,4-triazoles using a novel amine resin. Org. Lett 2001;3:3341–3344. [PubMed: 11594829]

27. Morris J, Wishika DG, Fang YA. Novel synthesis of 2-aminochromones via phosgeniminium salts. J. Org. Chem 1992;57:6502–6508.

28. Gall M, Kamdar BV, Lipton MF, Chidester CG, DuChamp DJ. Mannich reaction of heterocycles with dimethyl(methylen)-ammonium chloride: a high yield, one-step conversion of estazolam to adinazolam. J. Heterocycl. Chem 1988;25:1649–1661.

29. Arend M, Westermann B, Risch N. Modern variants of the mannich reaction. Angew. Chem., Int. Ed 1998;37:1044–1070.

30. Greiner E, Spetea M, Krassnig R, Schullner F, Aceto M, Harris LS, Traynor JR, Woods JH, Coop A, Schmidhammer H. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-Substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure–activity relationships. J. Med. Chem 2003;46:1758–1763. [PubMed: 12699394]

31. Coop A, Rothman RB, Dersch C, Partilla J, Porreca F, Davis P, Jacobson AE, Rice KC. δ Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole. J. Med. Chem 1999;42:1673–1679. [PubMed: 10229636]

32. Portoghese PS, Sultana M, Takemori AE. Design of peptidomimetic delta opioid receptor antagonists using the message–address concept. J. Med. Chem 1990;33:1714–1720. [PubMed: 2160538]

33. Ullrich T, Dersch CM, Rothman RB, Jacobson AE, Rice KC. Derivatives of 17-(2-methylallyl)-substituted noroxymorphone: variation of the delta address and its effects on affinity and selectivity for the delta opioid receptor. Bioorg. Med. Chem. Lett 2001;11:2883–2885. [PubMed: 11597422]

34. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc. Natl. Acad. Sci. U S A 2002;99:11934–11939. [PubMed: 12192085]

35. Schiller PW, Berezowska I, Nguyen TM, Schmidt R, Lemieux C, Chung NN, Falcone-Hindley ML, Yao W, Liu J, Iwama S, Smith AB 3rd, Hirschmann R. Novel ligands lacking a positive charge for the δ- and μ-opioid receptors. J. Med. Chem 2000;43:551–559. [PubMed: 10691681]

**Figure 1.**
Comparison of the structures of naltrindole and the present 1,2,4-triazoles.

**Figure 2.**
Up-regulation results of compounds **2** and **8**.

<sup>a</sup> See Table 1 for examples of R1, R2, and R3. (a) Viehe's salts, DCM, room temp, 5 h; (b) BBr3, DCM, room temp, 3 h; (c) trimethyl orthoformate, HOAc/DMF, room temp, 3 h; (d) Eschenmoser's salt, DMF, 80 °C, 8 h; (e) *N,N*-dimethylaminopropionic acid hydrochloride, DCC, toluene, room temp; (f) reflux, 8 h.

**Scheme 1.**
General Synthesis of Substituted 1,2,4-Triazoles<sup>a</sup>

**Table 1**

Structures and Opioid Receptor Binding Affinities for Substituted 1,2,4-Triazoles

| compd | $R_1$ | $R_2$ | $R_3$ | % inhibition[a] | | | $K_i$ (nM)[b] | | | selectivity ratio | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | δ | μ | κ | δ | μ | κ | δ/μ | δ/κ |
| 1 | 3-OCH$_3$ | 3-*tert*-butyl | H | 31 | 11 | 5 | >10000 | >10000 | >10000 | na | |
| 2 | 3-OH | 3-*tert*-butyl | H | 91 | 78 | 66 | 230 | 850 | 1500 | 3.70 | 6.52 |
| 3 | 3-OCH$_3$ | 4-*tert*-butyl | H | 8 | 9 | 8 | >10000 | >10000 | >10000 | na | |
| 4 | 3-OH | 4-*tert*-butyl | H | 54 | 16 | 16 | ~10000 | >10000 | >10000 | na | |
| 5 | 3-OH | 3-phenyl | H | 84 | 84 | 42 | 140 | 1000 | >10000 | 7.14 | >71.4 |
| 6 | 3-OH | 4-phenyl | H | 75 | 60 | 46 | 1500 | >10000 | >10000 | >6.66 | >6.66 |
| 7 | 3-OH | 3,4-(CH=CH)$_2$ | H | 68 | 48 | 27 | 2100 | >10000 | >10000 | >4.76 | >4.76 |
| 8 | 3-OH | 4-*tert*-butyl | N(CH$_3$)$_2$ | 94 | 32 | 6 | 50 | 4000 | >10000 | 80 | >200 |
| 9 | 3-OCH$_3$ | 4-*tert*-butyl | N(CH$_3$)$_2$ | 28 | 50 | 3 | >10000 | >10000 | >10000 | na | |
| 10 | 3-OH | 3-*tert*-butyl | N(CH$_3$)$_2$ | 76 | 19 | 6 | 1050 | >10000 | >10000 | >9.5 | >9.5 |
| 11 | 3-OH | 3-phenyl | N(CH$_3$)$_2$ | 86 | 23 | 8 | 150 | >10000 | >10000 | >66.6 | >66.6 |
| 12 | 3-OH | 4-phenyl | N(CH$_3$)$_2$ | 82 | 15 | 11 | 130 | >10000 | >10000 | >76.9 | >76.9 |
| 13 | 3-OH | 3,4-(CH=CH)$_2$ | N(CH$_3$)$_2$ | 68 | 48 | 27 | 480 | >10000 | >10000 | >20.8 | >20.8 |
| 14 | 4-OH | 4-*tert*-butyl | N(CH$_3$)$_2$ | 27 | 8 | 21 | >10000 | >10000 | >10000 | na | |
| 15 | 3-OH | 4-*tert*-butyl | N(CH$_2$CH$_2$)$_2$NCH$_3$ | 18 | 5 | 12 | >10000 | >10000 | >10000 | na | |
| 16 | 3-OH | 3-*tert*-butyl | CH$_2$N(CH$_3$)$_2$ | 65 | 27 | 10 | 2600 | >10000 | >10000 | >3.86 | >3.86 |
| 17 | 3-OH | 4-*tert*-butyl | CH$_2$N(CH$_3$)$_2$ | 88 | 20 | 9 | 460 | >10000 | >10000 | >21.6 | >21.6 |
| 18 | 3-OH | 4-*tert*-butyl | (CH$_2$)$_2$N(CH$_3$)$_2$ | 90 | 23 | 19 | 900 | >10000 | >10000 | >11.1 | >11.1 |

[a] Compounds, initially screened at 10 μM, are expressed as percentage inhibition of the reference compound which is normalized to 100%. (−)-[9−3*H*]bremazocine was used as the radiolabeled ligand.

[b] Inhibitory effect to (−)-[9−3*H*]bremazocine on membranes isolated from HEK 293 cells stably transfected with mouse (δ and μ) or rat (κ) opioid receptors. $K_i$ values are the average of two to three independent experiments.

**Table 2**

Relative Energies of Protonation[a] Obtained from HF/6−31G** ab Initio Calculations on Compound 8 Assuming Vacuum and Aqueous Conditions



| protonation site | vacuum[a] | aqueous[a] |
|---|---|---|
| $N_1$ | 1.07 | 0.00 |
| $N_2$ | 0.00 | 0.25 |
| $N_4$ | 56.85 | 53.28 |
| $N_{sub}$ | 25.29 | 13.30 |

[a]In units of kcal/mol.